questionsmedicales.fr
Facteurs biologiques
Antigènes
Isoantigènes
Antigènes d'histocompatibilité
Antigènes HLA
Antigènes HLA-B
Antigène HLA-B13
Antigène HLA-B13 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Polymérase Chain Reaction
Séquençage
Maladies auto-immunes
Infections virales
Greffe d'organe
Compatibilité tissulaire
Symptômes
5
Symptômes
Maladies associées
Antigènes HLA
Maladies auto-immunes
Conditions médicales
Symptômes
Allergies
Maladies auto-immunes
Prévention
5
Mode de vie sain
Gestion du stress
Tests génétiques
Surveillance préventive
Éducation
Gestion des risques
Traitements
5
Immunosuppresseurs
Thérapies ciblées
Traitement immunologique
Antigènes HLA
Traitement
Maladies associées
Efficacité des traitements
Réponse individuelle
Thérapie génique
Recherche médicale
Complications
5
Complications
Maladies auto-immunes
Gestion des complications
Récupération
Gravité
Évolution des maladies
Complications spécifiques
Maladies associées
Facteurs de risque
5
Facteurs de risque
Antécédents familiaux
Infections
Maladies auto-immunes
Tests génétiques
Évaluation médicale
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antigène HLA-B13 : Questions médicales les plus fréquentes",
"headline": "Antigène HLA-B13 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antigène HLA-B13 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-20",
"dateModified": "2025-02-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antigène HLA-B13"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antigènes HLA-B",
"url": "https://questionsmedicales.fr/mesh/D015235",
"about": {
"@type": "MedicalCondition",
"name": "Antigènes HLA-B",
"code": {
"@type": "MedicalCode",
"code": "D015235",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.050.705.552.450.380"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Antigène HLA-B13",
"alternateName": "HLA-B13 Antigen",
"code": {
"@type": "MedicalCode",
"code": "D059908",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Apostolos P Georgopoulos",
"url": "https://questionsmedicales.fr/author/Apostolos%20P%20Georgopoulos",
"affiliation": {
"@type": "Organization",
"name": "The HLA Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, USA."
}
},
{
"@type": "Person",
"name": "Lisa M James",
"url": "https://questionsmedicales.fr/author/Lisa%20M%20James",
"affiliation": {
"@type": "Organization",
"name": "The HLA Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, USA."
}
},
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Arie Admon",
"url": "https://questionsmedicales.fr/author/Arie%20Admon",
"affiliation": {
"@type": "Organization",
"name": "Faculty of Biology, Technion Israel Institute of Technology, Haifa, Israel admon@technion.ac.il Michael.peled@sheba.health.gov.il."
}
},
{
"@type": "Person",
"name": "Spyros A Charonis",
"url": "https://questionsmedicales.fr/author/Spyros%20A%20Charonis",
"affiliation": {
"@type": "Organization",
"name": "The HLA Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Involvement of complement peptides C3a and C5a in osteoarthritis pathology.",
"datePublished": "2022-05-20",
"url": "https://questionsmedicales.fr/article/35598724",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.peptides.2022.170815"
}
},
{
"@type": "ScholarlyArticle",
"name": "C5a complement levels in clinical remission AQP4-IgG-positive NMO patients.",
"datePublished": "2023-04-07",
"url": "https://questionsmedicales.fr/article/37024715",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s13760-023-02261-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Therapeutic Potential of Targeting Complement C5a Receptors in Diabetic Kidney Disease.",
"datePublished": "2023-05-15",
"url": "https://questionsmedicales.fr/article/37240105",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms24108758"
}
},
{
"@type": "ScholarlyArticle",
"name": "Overexpression of complement C5a indicates poor survival and therapeutic response in metastatic renal cell carcinoma.",
"datePublished": "2023-03-07",
"url": "https://questionsmedicales.fr/article/36883235",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/03936155231161366"
}
},
{
"@type": "ScholarlyArticle",
"name": "The efficacy and safety of complement C5a inhibitors for patients with severe COVID-19: a systematic review and meta-analysis.",
"datePublished": "2022-11-29",
"url": "https://questionsmedicales.fr/article/36399686",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/14787210.2022.2150165"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Antigènes",
"item": "https://questionsmedicales.fr/mesh/D000941"
},
{
"@type": "ListItem",
"position": 4,
"name": "Isoantigènes",
"item": "https://questionsmedicales.fr/mesh/D007519"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antigènes d'histocompatibilité",
"item": "https://questionsmedicales.fr/mesh/D006649"
},
{
"@type": "ListItem",
"position": 6,
"name": "Antigènes HLA",
"item": "https://questionsmedicales.fr/mesh/D006680"
},
{
"@type": "ListItem",
"position": 7,
"name": "Antigènes HLA-B",
"item": "https://questionsmedicales.fr/mesh/D015235"
},
{
"@type": "ListItem",
"position": 8,
"name": "Antigène HLA-B13",
"item": "https://questionsmedicales.fr/mesh/D059908"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antigène HLA-B13 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antigène HLA-B13",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antigène HLA-B13",
"description": "Comment diagnostiquer la présence de HLA-B13 ?\nQuels tests sont utilisés pour HLA-B13 ?\nHLA-B13 est-il associé à des maladies spécifiques ?\nPeut-on détecter HLA-B13 chez tous les individus ?\nQuel rôle joue HLA-B13 dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D059908?mesh_terms=Complement+C5a#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antigène HLA-B13",
"description": "Quels symptômes sont liés à HLA-B13 ?\nHLA-B13 cause-t-il des symptômes directs ?\nY a-t-il des symptômes spécifiques à HLA-B13 ?\nHLA-B13 est-il lié à des symptômes allergiques ?\nLes symptômes varient selon l'ethnicité ?",
"url": "https://questionsmedicales.fr/mesh/D059908?mesh_terms=Complement+C5a#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antigène HLA-B13",
"description": "Peut-on prévenir les maladies liées à HLA-B13 ?\nY a-t-il des mesures préventives spécifiques ?\nLa vaccination aide-t-elle contre HLA-B13 ?\nLes tests génétiques peuvent-ils prévenir des maladies ?\nL'éducation sur HLA-B13 est-elle importante ?",
"url": "https://questionsmedicales.fr/mesh/D059908?mesh_terms=Complement+C5a#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antigène HLA-B13",
"description": "Quels traitements sont disponibles pour les maladies liées à HLA-B13 ?\nHLA-B13 influence-t-il le choix du traitement ?\nY a-t-il des traitements spécifiques pour HLA-B13 ?\nLes traitements sont-ils efficaces pour HLA-B13 ?\nDes thérapies géniques sont-elles envisagées pour HLA-B13 ?",
"url": "https://questionsmedicales.fr/mesh/D059908?mesh_terms=Complement+C5a#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antigène HLA-B13",
"description": "Quelles complications peuvent survenir avec HLA-B13 ?\nHLA-B13 augmente-t-il le risque de cancer ?\nLes complications sont-elles réversibles ?\nHLA-B13 influence-t-il la gravité des maladies ?\nY a-t-il des complications spécifiques à HLA-B13 ?",
"url": "https://questionsmedicales.fr/mesh/D059908?mesh_terms=Complement+C5a#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antigène HLA-B13",
"description": "Quels sont les facteurs de risque pour HLA-B13 ?\nL'ethnicité influence-t-elle HLA-B13 ?\nLes infections augmentent-elles le risque lié à HLA-B13 ?\nLe mode de vie affecte-t-il HLA-B13 ?\nY a-t-il des tests pour évaluer les facteurs de risque ?",
"url": "https://questionsmedicales.fr/mesh/D059908?mesh_terms=Complement+C5a#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la présence de HLA-B13 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un test sanguin pour déterminer le typage HLA est utilisé pour diagnostiquer HLA-B13."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour HLA-B13 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de typage HLA, comme la PCR et le séquençage, sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "HLA-B13 est-il associé à des maladies spécifiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, HLA-B13 est lié à certaines maladies auto-immunes et infections virales."
}
},
{
"@type": "Question",
"name": "Peut-on détecter HLA-B13 chez tous les individus ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, HLA-B13 est présent chez une partie de la population, selon l'ethnicité."
}
},
{
"@type": "Question",
"name": "Quel rôle joue HLA-B13 dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il aide à évaluer la compatibilité pour les greffes et à identifier des risques de maladies."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à HLA-B13 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient selon les maladies associées, comme des douleurs articulaires ou éruptions."
}
},
{
"@type": "Question",
"name": "HLA-B13 cause-t-il des symptômes directs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, HLA-B13 lui-même ne cause pas de symptômes, mais il est associé à des maladies."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques à HLA-B13 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes dépendent des conditions associées, pas de HLA-B13 directement."
}
},
{
"@type": "Question",
"name": "HLA-B13 est-il lié à des symptômes allergiques ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "HLA-B13 n'est pas directement lié aux allergies, mais à des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Les symptômes varient selon l'ethnicité ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la prévalence de HLA-B13 et les maladies associées peuvent varier selon l'ethnicité."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les maladies liées à HLA-B13 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un suivi médical régulier peut aider à détecter précocement."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives spécifiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des mesures préventives incluent un mode de vie sain et la gestion du stress."
}
},
{
"@type": "Question",
"name": "La vaccination aide-t-elle contre HLA-B13 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vaccination peut aider à prévenir certaines infections, mais pas directement HLA-B13."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils prévenir des maladies ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les risques et permettre une surveillance préventive."
}
},
{
"@type": "Question",
"name": "L'éducation sur HLA-B13 est-elle importante ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation sur HLA-B13 et ses implications peut aider à mieux gérer les risques."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les maladies liées à HLA-B13 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des immunosuppresseurs et des thérapies ciblées selon la maladie."
}
},
{
"@type": "Question",
"name": "HLA-B13 influence-t-il le choix du traitement ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la présence de HLA-B13 peut influencer le choix des traitements immunologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements spécifiques pour HLA-B13 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement spécifique pour HLA-B13, mais pour les maladies associées."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces pour HLA-B13 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité des traitements dépend de la maladie associée et de la réponse individuelle."
}
},
{
"@type": "Question",
"name": "Des thérapies géniques sont-elles envisagées pour HLA-B13 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur les thérapies géniques, mais elles ne sont pas encore disponibles."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec HLA-B13 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des maladies auto-immunes et des réactions aux greffes."
}
},
{
"@type": "Question",
"name": "HLA-B13 augmente-t-il le risque de cancer ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent un lien entre HLA-B13 et un risque accru de certains cancers."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "HLA-B13 influence-t-il la gravité des maladies ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, HLA-B13 peut influencer la gravité et l'évolution de certaines maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications spécifiques à HLA-B13 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications spécifiques dépendent des maladies associées, pas de HLA-B13 lui-même."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour HLA-B13 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, l'ethnicité et des infections virales."
}
},
{
"@type": "Question",
"name": "L'ethnicité influence-t-elle HLA-B13 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la prévalence de HLA-B13 varie selon les groupes ethniques et les populations."
}
},
{
"@type": "Question",
"name": "Les infections augmentent-elles le risque lié à HLA-B13 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections peuvent déclencher des maladies auto-immunes chez les porteurs de HLA-B13."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il HLA-B13 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut réduire le risque de maladies associées à HLA-B13."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests pour évaluer les facteurs de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests génétiques et des évaluations médicales peuvent aider à identifier les risques."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 14/02/2025
Contenu vérifié selon les dernières recommandations médicales
7 publications dans cette catégorie
Affiliations :
The HLA Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, USA.
Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN, USA.
Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, USA.
Department of Neurology, University of Minnesota Medical School, Minneapolis, MN, USA.
7 publications dans cette catégorie
Affiliations :
The HLA Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, USA.
Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN, USA.
Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, USA.
3 publications dans cette catégorie
Publications dans "Antigène HLA-B13" :
3 publications dans cette catégorie
Affiliations :
Faculty of Biology, Technion Israel Institute of Technology, Haifa, Israel admon@technion.ac.il Michael.peled@sheba.health.gov.il.
Publications dans "Antigène HLA-B13" :
2 publications dans cette catégorie
Affiliations :
The HLA Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, USA.
Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN, USA.
Publications dans "Antigène HLA-B13" :
2 publications dans cette catégorie
Affiliations :
The HLA Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, USA.
Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN, USA.
Publications dans "Antigène HLA-B13" :
2 publications dans cette catégorie
Affiliations :
Centre for Inflammatory Diseases, Monash University, Clayton, Victoria, 3168, Australia; Dept. of Nephrology, Monash Health, Clayton, Victoria, 3168, Australia; Dept. of Paediatric Nephrology, Monash Health, Clayton, Victoria, 3168, Australia.
Publications dans "Antigène HLA-B13" :
2 publications dans cette catégorie
Affiliations :
Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands.
Netherlands Proteomics Centre, Utrecht University, Utrecht, Netherlands.
Publications dans "Antigène HLA-B13" :
2 publications dans cette catégorie
Affiliations :
Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands.
Netherlands Proteomics Centre, Utrecht University, Utrecht, Netherlands.
Publications dans "Antigène HLA-B13" :
2 publications dans cette catégorie
Affiliations :
Faculty of Biology, Technion Israel Institute of Technology, Haifa, Israel.
Publications dans "Antigène HLA-B13" :
2 publications dans cette catégorie
Affiliations :
From the ‡Department of Biology, Technion, Israel Institute of Technology, Haifa 32000, Israel.
Publications dans "Antigène HLA-B13" :
2 publications dans cette catégorie
Affiliations :
‡‡Eberhard Karls Universität Tübingen, Department of Immunology, Auf der Morgenstelle 15,72076 Tubingen, Germany.
Publications dans "Antigène HLA-B13" :
2 publications dans cette catégorie
Affiliations :
Department of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, CA, United States.
Publications dans "Antigène HLA-B13" :
2 publications dans cette catégorie
Affiliations :
Center for Computational and Genomic Medicine, Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA, United States.
Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Publications dans "Antigène HLA-B13" :
2 publications dans cette catégorie
Affiliations :
Janssen Research & Development, Turnhoutseweg 30, BE-2340, Beerse, Belgium.
Publications dans "Antigène HLA-B13" :
2 publications dans cette catégorie
Affiliations :
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: sferrone@mgh.harvard.edu.
Publications dans "Antigène HLA-B13" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Protein Biochemistry, Department of Biology, Chemistry and Pharmacy, Freie Universität Berlin, Thielallee 63, 14195, Berlin, Germany. malvaro@zedat.fu-berlin.de.
Publications dans "Antigène HLA-B13" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Protein Biochemistry, Department of Biology, Chemistry and Pharmacy, Freie Universität Berlin, Thielallee 63, 14195, Berlin, Germany. chfreund@zedat.fu-berlin.de.
Publications dans "Antigène HLA-B13" :
1 publication dans cette catégorie
Affiliations :
Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
Publications dans "Antigène HLA-B13" :
1 publication dans cette catégorie
Affiliations :
Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI, United States.
Publications dans "Antigène HLA-B13" :
Osteoarthritis (OA) affects more than 500 million people worldwide and is among the five diseases in Germany causing the highest suffering of the patients and cost for the society. The quality of life...
Neuromyelitis Optica Spectrum Disorders (NMOSD) is an antibody-mediated disorder of the Central Nervous System where a leading role of the complement system has been demonstrated....
To measure the levels of complement factors C3, C4 and C5a in serum and plasma of clinical remission patients with AQP4-IgG + NMOSD....
Twelve patients with NMOSD AQP4 + according to 2015 criteria from a General Hospital in Buenos Aires, Argentina, were included in the study, and 19 age- and sex-matched healthy volunteers as a control...
The complement factors, C3, C4, and C5a were measured in all samples. The mean concentration of C3 was 130.7 mg/dl (SD 16.1 mg/dl), and the mean concentration of C4 was 21.6 mg/dl (SD 4.8 mg/dl); both...
In conclusion, the present study demonstrates that plasma C5a may be interesting to investigate as a potential biomarker of disease activity in NMOSD, in a larger and prospective cohort....
Diabetic kidney disease (DKD) affects 30-40% of patients with diabetes and is currently the leading cause of end-stage renal disease (ESRD). The activation of the complement cascade, a highly conserve...
Complement C5a is an important component of the innate immune system. An increasing number of reports have revealed the relevance of C5a in tumor progression; however, its exact role in metastatic ren...
We evaluated C5a expression in tumor tissue microarrays of 231 mRCC patients and analyzed the relationship between C5a levels and clinical outcomes, and the expression of epithelial-mesenchymal transi...
High C5a expression was associated with poor therapeutic responses, poor overall and progression-free survival, and high expression of EMT-related proteins and PD-1/PD-L1 in mRCC patients. Exogenous C...
Our findings indicate that elevated C5a expression is associated with poor outcomes in patients with mRCC, and this effect may be partly attributed to the ability of C5a to promote EMT and PD-1/PD-L1 ...
The clinical efficacy and safety of complement C5a inhibitors for patients with severe COVID-19 remains unclear....
The PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were searched from their inception to 27 September 2022. Only studies that assessed the usefulness of C5a inhibitors for the trea...
Six studies, including four randomized controlled trials (RCTs) and two non-RCTs, were included. The study group receiving C5a inhibitors had a significantly lower risk of mortality compared with the ...
C5a inhibitors could help reduce the risk of mortality in patients with severe COVID-19 infection while being as safe as placebos. These findings support the promising role of C5a inhibitors in the tr...
Involvement of lower gastrointestinal tract (LGI) occurs in 60% of patients with graft-versus-host-disease (GVHD). Complement components C3 and C5 are involved in GVHD pathogenesis. In this phase 2a s...
Numerous publications have underlined the link between complement C5a and the clinical course of COVID-19. We previously reported that levels of C5a remain high in the group of severely ill patients u...
To examine concentrations of circulating antibodies targeting C3a and C5a complement receptors in antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) and analyze their associati...
Concentrations of antibodies against C3a and C5a complement receptors (anti-C3aR and anti-C5aR) and plasma complement fragments C3a and C5a were determined in patients with AAV (n = 110; granulomatosi...
In AAV, anti-C3aR and anti-C5aR antibodies were decreased (P = 0.0026 and P ≤ 0.0001, respectively). In remission, anti-C3aR antibody concentrations rose to values comparable to healthy donors, wherea...
Low concentrations of anti-C5aR antibodies reflect disease activity and are associated with an increased risk for relapse in AAV....
A complement effect on homeostasis during infection is determined by both cytotoxic (activate complement component 5 (C5a) terminal cytotoxic complex (TCC)), and cytoprotective elements (complement fa...
The conjunctiva has immune-responsive properties to protect the eye from infections. Its innate immune system reacts against external pathogens, such as fungi. The complement factor C5a is an importan...